enGene Holdings Inc.
23.5M
$88.06M
-3.14
$-2.29
No price alerts set. Add an alert to get notified!
-3.14
2.20
$-2.29
-69.94%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ACIU
AC Immune S.A.
|
$2.92 | -1.68% | -3.39 | $297.18M | 0.14 |
|
ALT
Altimmune, Inc.
|
$3.04 | -6.75% | -3.47 | $268.30M | 0.16 |
|
AMRN
Amarin Corporation plc
|
$14.84 | -0.40% | -9.18 | $306.93M | 0.01 |
|
ANNX
Annexon, Inc.
|
$5.52 | -3.16% | -5.46 | $660.16M | 0.12 |
|
ANRO
Alto Neuroscience, Inc.
|
$24.07 | -1.71% | -12.15 | $768.93M | 0.16 |
|
CLLS
Cellectis S.A.
|
$3.86 | -2.28% | -5.53 | $386.94M | 1.58 |
|
DBVT
DBV Technologies S.A.
|
$19.99 | -0.55% | -10.07 | $478.20M | 0.03 |
|
KRRO
Korro Bio, Inc.
|
$12.89 | -3.37% | -1.32 | $128.30M | 0.36 |
|
LRMR
Larimar Therapeutics, Inc.
|
$4.00 | -3.61% | -2.06 | $342.31M | 0.05 |
|
SLN
Silence Therapeutics plc
|
$6.95 | -5.57% | -4.37 | $328.28M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$12.25
$1.70
$0.00
0.00%
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
